Gilder Gagnon Howe & Co. LLC cut its position in shares of DexCom Inc. (NASDAQ:DXCM) by 2.6% during the second quarter, Holdings Channel reports. The firm owned 786,047 shares of the medical device company’s stock after selling 21,073 shares during the period. DexCom makes up about 1.2% of Gilder Gagnon Howe & Co. LLC’s portfolio, making the stock its 26th largest position. Gilder Gagnon Howe & Co. LLC’s holdings in DexCom were worth $62,357,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Bridger Management LLC purchased a new position in DexCom during the first quarter worth about $56,651,000. State Street Corp boosted its position in DexCom by 7.2% in the first quarter. State Street Corp now owns 1,055,774 shares of the medical device company’s stock valued at $71,699,000 after buying an additional 71,009 shares during the period. American Century Companies Inc. boosted its position in DexCom by 7.3% in the second quarter. American Century Companies Inc. now owns 806,639 shares of the medical device company’s stock valued at $63,991,000 after buying an additional 54,684 shares during the period. Renaissance Technologies LLC boosted its position in DexCom by 17.9% in the first quarter. Renaissance Technologies LLC now owns 817,943 shares of the medical device company’s stock valued at $55,547,000 after buying an additional 124,000 shares during the period. Finally, Calamos Advisors LLC bought a new position in DexCom during the second quarter valued at $22,764,000. Institutional investors own 99.28% of the company’s stock.
DexCom Inc. (NASDAQ:DXCM) traded up 0.04% during midday trading on Wednesday, reaching $82.55. 343,039 shares of the company traded hands. DexCom Inc. has a 12-month low of $47.92 and a 12-month high of $96.38. The stock’s market capitalization is $6.92 billion. The company has a 50 day moving average of $89.12 and a 200-day moving average of $78.97.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.12. The business had revenue of $137.30 million for the quarter, compared to the consensus estimate of $132.48 million. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. DexCom’s revenue was up 47.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.05) EPS. Equities analysts anticipate that DexCom Inc. will post ($0.57) EPS for the current fiscal year.
DXCM has been the subject of several research analyst reports. Zacks Investment Research cut shares of DexCom from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 4th. BMO Capital Markets initiated coverage on shares of DexCom in a research report on Friday, September 16th. They issued an “outperform” rating and a $112.00 price objective for the company. Desjardins upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Friday, September 16th. Leerink Swann restated an “outperform” rating and issued a $90.00 price objective on shares of DexCom in a research report on Wednesday, July 20th. Finally, BTIG Research cut shares of DexCom from a “buy” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Wednesday, September 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $95.40.
In related news, CEO Kevin R. Sayer sold 7,000 shares of DexCom stock in a transaction on Friday, October 14th. The shares were sold at an average price of $81.87, for a total transaction of $573,090.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew K. Balo sold 5,000 shares of DexCom stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $88.14, for a total transaction of $440,700.00. Following the transaction, the executive vice president now directly owns 134,979 shares of the company’s stock, valued at approximately $11,897,049.06. The disclosure for this sale can be found here. Insiders own 2.80% of the company’s stock.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.